CTRI/2022/12/048540
尚未招募
3 期
Phase-3, Multicentric, open label trial to evaluate the efficacy of Hydroxyurea and Thalidomide in Thalassemia patients - HATT Trial
概览
- 阶段
- 3 期
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- DGAFMS
- 状态
- 尚未招募
- 最后更新
- 3年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •1\. Diagnosis of transfusion\-dependent thalassemia
- •2\. ECOG: 0 to 2 scores
- •3\. Blood transfusion to maintain the Hb or level of Hb \<9g/dl if not transfused
- •4\. Sign an informed consent agreeing to the clinical trial participation
排除标准
- •1\. Patients with comorbidities like severe heart or lung diseases, liver dysfunction, renal dysfunction, malignancy, cerebrovascular disease, or other serious primary diseases
- •2\. Patients allergic to the drug ingredients
- •3\. Patients with any mental health problem
- •4\. Patients had participated in other drug clinical trials in the past 1 month
- •5\. Patients had a history of venous or arterial thrombosis
- •6\. Childbearing age unwilling to use contraceptive measures
- •7\. In certain circumstances the researchers determined it was not suitable for the research
结局指标
主要结局
未指定
相似试验
尚未招募
3 期
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisGeneralized Pustular PsoriasisErythrodermic PsoriasisJPRN-jRCT2071230104akano Masayoshi16
未知
3 期
Phase 3, multicenter, open-label study to evaluate the safety and efficacy of long-term administration of TAK-085 to the patients with hypertriglyceridemiaJPRN-jRCT2080220904Takeda Pharmaceutical Company Limited
进行中（未招募）
3 期
Study to evaluate the efficacy, pharmacokinetics, safety, and immunogenicity of subcutaneously administered ustekinumab or guselkumab in pediatric participants with active juvenile psoriatic arthritisISRCTN49107623Janssen-Cilag International NV80
进行中（未招募）
3 期
A Phase III study to evaluate the efficacy and safety of NRL-1 intranasally administered in Japanese pediatric patients with status epilepticusJPRN-jRCT2031220265akagawa Eiji15
进行中（未招募）
1 期
Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148Irritability Associated With Autism Spectrum DisorderTherapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]EUCTR2018-004899-35-Outside-EU/EEAOtsuka Pharmaceutical Development & Commercialization, Inc.